In the May Newsletter, we posted an article about the advances in artificial intelligence use in the drug safety and pharmacovigilance sector. Here we highlight how Genpact’s new pharmacovigilance Artificial Intelligence (PVAI) solution is promising to transform drug safety data management and reporting. Genpact’s solution will be the life sciences industry’s first fully integrated, end-to-end adverse event (AE) processing programme, aimed to dramatically reduce the effort of processing AEs. It is also designed to enable an AI-driven level of real-time predictive analytics and actionable insight not previously possible.
Increasing AE volumes coupled with mounting pressure to improve quality and compliance while reducing costs has led to pharma companies finding breakthrough solutions to help them transform and streamline their pharmacovigilance operations.
What does Genpact’s PVAI offer?
Genpact’s solution provides integrated optical character recognition, robotic process automation, natural language processing and machine learning technologies which automatically extract and code AE data from source documents. This will eliminate manual workflow, save time and resource and help establish a scalable PV model. One key feature is the system continuously learns from incoming AE data thereby accumulates predictive insights as more and more AEs are processed.
The Vice President of Genpact issued the following statement “Industry leaders have stated that the current manually-intensive approach to AE processing is simply not sustainable and needs an innovative approach. Through robust pilot testing with clients, our new PVAI solution has proven that the vast majority of case processing can be successfully automated in a fraction of the time and cost”.
Genpact helps pharma companies to achieve global growth, reduce costs, increase speed to market and improve regulatory compliance. They offer a range of digital solutions, analytics services and business process transformation expertise.